AbbVie Presents Data For Navitoclax Combination For JAK Inhibitor-Naïve Myelofibrosis Patients https://www.proinvestor.com/investornyt/914628/abbvie-presents-data-for-navitoclax-combination-for-jak-inhibitor-naive-myelofibrosis-patients
Teva: Studies Show Efficacy Of Fremanezumab In Patients With Migraine And Major Depressive Disorder https://www.proinvestor.com/investornyt/876299/teva-studies-show-efficacy-of-fremanezumab-in-patients-with-migraine-and-major-depressive-disorder
Lundbecks nye vækstmotor er "slam dunk" mener JPMorgan https://www.proinvestor.com/investornyt/862415/lundbecks-nye-vaekstmotor-er-slam-dunk-mener-jpmorgan
Here's Why Abbott's a Great Buy Even if COVID Testing Revenue Falls https://www.proinvestor.com/investornyt
/803915/heres-why-abbotts-a-great-buy-even-if-covid-testing-revenue-falls
Novo Q4: Sigter over analytikernes prognose for 2022 - NY
https://www.proinvestor.com/investornyt/774806/novo-q4-sigter-over-analytikernes-prognose-for-2022-ny
Alnylam Submits Applications In U.S, EU To Support Label Expansion For Oxlumo For PH1 Treatment https://www.proinvestor.com/investornyt/749126/alnylam-submits-applications-in-us-eu-to-support-label-expansion-for-oxlumo-for-ph1-treatment